



European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands



Oxford Clinical Trials Research Unit
Botnar Research Unit
Windmill Road
Oxford
OX3 7LF

Date: 21 June 2021

Dear European Medicines Agency

Results summary for EudraCT upload

Trial Title: Adalimumab in COVID-19 to prevent respiratory failure in community care (AVID-CC): A randomised controlled trial

CESP REF: 1268838

IDs: EudraCT No: 2020-003628-18; MHRA CTA: 21584/0433/001-0001; IRAS ID: 287434

Oxford Clinical Trials Research Unit, on behalf of the Sponsor (University of Oxford), submitted an end of trial notification to the MHRA and REC on 24th May 2021. The trial is now closed. No patients were screened or recruited.

The aim of the study was to establish whether adalimumab has a clinically beneficial effect in COVID-19 positive residents in the community, largely from care homes. Care homes were hit very hard by COVID outbreaks, however the vaccination program in the UK has been successful in protecting residents against serious disease. Whilst there are still incidences of COVID-19 in vaccinated residents of care homes, very few of them are going onto develop severe disease - the primary endpoint for the study. AVID-CC was open to recruitment for a month but due to the efficiency of the vaccine program, no suitable subjects were identified. In light of this, a substantial amendment was submitted in April for a temporary halt to recruitment. Following the temporary halt, Duncan Richards, Chief Investigator, met with AVID-CC stakeholders and funders to review possible options going forward. It was agreed with that there wasn't an amendment that we could implement to the existing protocol that would deliver a clinically meaningful result. With regret it was agreed that we should therefore bring the study to a formal close.

If you require any further information, please email avid-cc@ndorms.ox.ac.uk

Best wishes,

Lucy Cureton

AVID-CC Trial Manager

Oxford Clinical Trials Research Unit

Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences (NDORMS)

AVID-CC@ndorms.ox.ac.uk